From DNA to AI: Progress and Hope in Vitiligo Research (Ep. 2)

Discover the future of vitiligo treatment in our latest episode, where we spotlight cutting-edge therapies transforming care for this complex condition. From Incyte's Opzelura, the first FDA-approved drug for vitiligo, to Temprian Therapeutics’ DNA-based treatments and Clinuvel’s synthetic hormones for full-body repigmentation, we explore the innovations redefining the field.   Learn how industry leaders like Amgen and Pfizer are moving beyond cosmetic solutions with advanced targeted therapies. Amgen’s AMG-714 blocks interleukin-15 to protect melanocytes, while Pfizer’s oral drug Litfulo targets immune pathways for systemic repigmentation. We also delve into the role of AI in diagnostics, featuring Skinopathy’s groundbreaking collaborations.   This episode captures the excitement and momentum driving vitiligo research and development. With these advancements, the future looks promising for more effective, accessible, and personalized treatments. Join us for an insightful dive into the breakthroughs offering hope to millions.